CliffBio
small molecule

ERYTHROMYCIN LACTOBIONATE

ERYTHROMYCIN LACTOBIONATE

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameERYTHROMYCIN LACTOBIONATE
Active ingredientERYTHROMYCIN LACTOBIONATE
StrengthEQ 500MG BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 2022
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ERYTHROMYCIN LACTOBIONATE patent cliff — loss of exclusivity — | CliffBio